Summary
FOLFOX4 (leucovorin, 5-fluorouracil, and oxaliplatin) has been the standard adjuvant therapy for resected stage III colon cancer since 2004, producing 3-year disease-free survival rates of ∼70%. The aim of the Combination Chemotherapy with or Without Cetuximab in Treating Patients with Stage III Colon Cancer That Was Completely Removed by Surgery [PETACC-8; NCT00265811] trial was to assess the potential benefit of adding cetuximab to standard treatment for colon cancer.
- Gastrointestinal Cancers
- Adjuvant/Neoadjuvant Therapy
- Oncology Clinical Trials
- © 2012 MD Conference Express®